US equities |
SPCX $166.71 ▲+4.88% NVDA $236.81 ▲+1.22% MU $1,064.12 ▼-1.00% TSLA $377.50 ▲+1.86% MSFT $526.55 ▲+1.74% SNDK $1,713.46 ▼-0.38% INTC $117.20 ▼-1.78% META $745.00 ▲+2.32%
FinancialContent

Cyclacel Pharmaceuticals, Inc. - Common Stock (NQ:CYCC)

6.365 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyclacel Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
From Cyclacel
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time for another dive into the biggest pre-market stock movers as we check out all the latest news for Tuesday morning! 
Via InvestorPlace
News headline image
Recap: Cyclacel Pharmaceuticals Q1 Earnings ↗
 
Via Benzinga
News headline image
Oppenheimer Maintains Outperform Rating for Cyclacel Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740. 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
A Preview Of Cyclacel Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
From Cyclacel
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
From Cyclacel
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
Earnings Outlook For Cyclacel Pharmaceuticals ↗
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients 
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Hosting Research & Development Day
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma - 
From Cyclacel
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We've got the news behind the biggest pre-market stock movers for Wednesday morning that traders need to know about this morning! 
Via InvestorPlace
News headline image
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday ↗
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday. 
Via Benzinga
News headline image
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66. 
Via Benzinga
News headline image
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday ↗
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results. 
Via Benzinga
News headline image
Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >